Post-exposure prophylaxis with SA58 (anti-SARS-COV-2 monoclonal antibody) nasal spray for the prevention of symptomatic COVID-19 in healthy adult workers: a randomized, single-blind, placebo-controlled clinical study*

Monoclonal antibodies (mAbs) and the post-exposure prophylaxis (PEP) with mAbs represent a very important public health strategy against coronavirus disease 2019 (COVID-19). This study has assessed a new Anti-SARS-COV-2 mAb (SA58) Nasal Spray for PEP against COVID-19 in healthy adults aged 18 years...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Rui, Zeng, Gang, Yu, Jianxing, Meng, Xing, Chen, Xiaoyou, Li, Jing, Xie, Xiaoliang, Lian, Xiaojuan, Zhang, Zhiyun, Cao, Yunlong, Yin, Weidong, Jin, Ronghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Coronaviruses
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10215016/
https://www.ncbi.nlm.nih.gov/pubmed/37157134
http://dx.doi.org/10.1080/22221751.2023.2212806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10215016/
https://www.ncbi.nlm.nih.gov/pubmed/37157134
http://dx.doi.org/10.1080/22221751.2023.2212806

Ejemplares similares